anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | Investor Presentation Deck | 42 slides

42 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvalent | Investor Presentation Deck | 42 slides

Nuvalent · 2024-04
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 4 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Traction 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a 2x2 grid layout to present key company metrics.summarize
Open slide detailLoop · Golden Circle
04
present_solution
Open slide detail
05
The slide uses a timeline-based structure to demonstrate historical progress and future financial stability.show_traction
Open slide detailBeat · Traction
06
The slide uses a timeline visual to connect high-level goals with specific 2024 milestones.plan_implementation
Open slide detail
07
The slide uses a split layout with a left-hand sidebar for board/advisors and a right-hand grid for the leadership team.other
Open slide detail
08
The slide uses a standard pharmaceutical pipeline visualization format.plan_implementation
Open slide detail
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) and their respective treatment challenges.compare_peers
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
Uses a case study (Osimertinib) to validate the proposed strategy for ALK/ROS1 targets.present_solution
Open slide detailBeat · Solution
11
The chart uses a bar-horizontal format to compare sales figures for specific drugs (Alectinib, Crizotinib) against a group of 'Other' TKIs.size_opportunity
Open slide detailBeat · Market Size
12
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical development parameters.present_solution
Open slide detail
13
The slide uses a timeline-based framework to map treatment lines (1L, 2L, 3L+) against clinical challenges.present_framework
Open slide detail
14
The slide uses a matrix-style comparison to highlight the superior coverage of NVL-655 compared to 1st, 2nd, and 3rd generation inhibitors.compare_peers
Open slide detail
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.present_solution
Open slide detail
16
The slide uses two distinct chart types (bar and scatter) to demonstrate pharmacological advantages.present_solution
Open slide detail
17
Includes detailed patient enrollment breakdown by dose cohort and trial phase.analyze_data
Open slide detail
18
Clinical trial baseline characteristics table.analyze_data
Open slide detail
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.analyze_data
Open slide detail
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 in NSCLC patients.show_traction
Open slide detail
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.show_traction
Open slide detail
22
Includes two patient case studies with MRI scans showing tumor reduction.illustrate_case
Open slide detail
23
Data cut-off: 8 Aug 2023. N=93 patients.analyze_data
Open slide detail
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mshow_traction
Open slide detail
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.present_solution
Open slide detail
26
Includes a table detailing patient cohorts and study objectives.plan_implementation
Open slide detail
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.present_solution
Open slide detail
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.frame_problem
Open slide detail
29
The slide uses a visual comparison matrix to highlight the therapeutic advantages of Zidesamtinib.compare_peers
Open slide detail
30
The slide uses three distinct chart types to demonstrate competitive superiority in potency, CNS penetration, and selectivity.present_solution
Open slide detail
31
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.analyze_data
Open slide detail
32
Clinical trial baseline characteristics table.analyze_data
Open slide detail
33
Includes a waterfall plot and a summary table of best responses.show_traction
Open slide detail
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.show_traction
Open slide detail
35
Data from ARROS-1 Phase 1 trial.analyze_data
Open slide detail
36
The slide highlights the Recommended Phase 2 Dose (RP2D) selection based on safety and PK data.show_traction
Open slide detail
37
The slide uses a comparative framework to contrast the 2L+ (salvage) and 1L (front-line) market opportunities.present_solution
Open slide detail
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.plan_implementation
Open slide detail
39
The slide uses a 'ribbon' style callout box on the right for the 'At a Glance' summary.present_solution
Open slide detail
40
The slide uses dot plots to show IC50 and selectivity index across various cell lines, and a bar chart for brain exposure in rats.present_solution
Open slide detail
41
The slide uses a timeline framework to connect current clinical status to the 'OnTarget 2026' mission.plan_implementation
Open slide detail
42
front_matter
Open slide detail